NCT00964171View on ClinicalTrials.gov

Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

19

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Pancreatic Cancer

Interventions

DRUG

Efavirenz 600mg

Trial Locations (1)

33076

Institut Bergonie, Bordeaux

Sponsors

Lead Sponsor

Institut Bergonié

All Listed Sponsors

lead

Institut Bergonié

OTHER